{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-085641","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2024-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.104966+00:00","generated_at":"2026-05-30T21:00:38.230541+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Emmaus Life Sciences board changes: George Sekulich resigns, Jon Kuwahara appointed","bullets":["George Sekulich resigned from board on Sep 30, 2024, after his termination as Chief Commercial Officer on Oct 4.","Jon Kuwahara appointed to fill vacancy effective Oct 1, 2024; also named Chair of Audit Committee.","Kuwahara served as Emmaus director from Jan 2016 to Sep 2018; now VP-Finance at Crinetics Pharmaceuticals (CRNX).","No family relationships or transactions requiring disclosure under Item 404(a) exist.","Kuwahara is a CPA with a BBA from University of Hawaii; prior roles at Novus Therapeutics and other life sciences firms."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-085641","json":"https://secwatch.observer/filing/0001213900-24-085641.json","markdown":"https://secwatch.observer/filing/0001213900-24-085641.md","text":"https://secwatch.observer/filing/0001213900-24-085641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390024085641/0001213900-24-085641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390024085641/ea0216701-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:00:38.230541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25cc4d4597","claim":"Jon Kuwahara was appointed as Director and Chair of Audit Committee at Emmaus Life Sciences, Inc..","evidence_excerpt":"the Board appointed Jon Kuwahara to fill the resulting vacancy on the Board of Directors. The Board also appointed Mr. Kuwahara to serve as the Chair of the two-person Audit Committee.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390024085641/0001213900-24-085641-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director and Chair of Audit Committee"}]},{"claim_id":"6682fa24a4","claim":"George Sekulich resigned as Director at Emmaus Life Sciences, Inc..","evidence_excerpt":"On September 30, 2024, George Sekulich resigned as a member of the Board of Directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390024085641/0001213900-24-085641-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}]},{"claim_id":"b1afbc6dee","claim":"George Sekulich was terminated as Chief Commercial Officer at Emmaus Life Sciences, Inc..","evidence_excerpt":"in connection with the termination of his employment as our Chief Commercial Officer on October 4, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390024085641/0001213900-24-085641-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Commercial Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}